Skip to content

Released Mar 16, 2023, after the close

10-K filed Mar 16, 2023, 75 days after period end · 0001390478-23-000005

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derived— vs Q4 2021no prior Q3 2022 on file
Net Income-$9.12MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$9,446,000N/M
Operating Cash Flowderived-$5,152,000N/M

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019derived from reported figures
Revenue$0.00$0.00$1.90M—
Net Income-$9.12M-$6.60M-$3.72M-$7.42M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR